Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine

R. Catane, J. Kaufman, A. Mittelman, G. P. Murphy

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


We treated 21 patients with stage D prostatic adenocarcinoma who had had unsuccessful hormonal therapy with a combination of 600 mg. per M.2 per day estramustine phosphate and 15 mg. per M.2 per day prednismustine in daily oral doses. Estramustine is a combination of estradiol and nitrogen mustard, and alone has shown objective responses in advanced prostatic cancer. Prednimustine is an ester of chlorambucil and prednisone. The preliminary results (after 2 to 9 months of therapy) show 5 patients (24 per cent) with objective responses and 9 (44 per cent) with subjective improvement. Only 5 patients (24 per cent) did not benefit from the drug and 7 patients (33 per cent) are stable. These preliminary results indicate the possible advantage of adding an alkylating agent (prednimustine) to estramustine in advanced prostatic carcinoma.

Original languageEnglish
Pages (from-to)332-336
Number of pages5
JournalJournal of Urology
Issue number3
StatePublished - 1977
Externally publishedYes


Dive into the research topics of 'Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine'. Together they form a unique fingerprint.

Cite this